Zacks Research Issues Pessimistic Outlook for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.93 per share for the quarter, down from their previous estimate of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.60 EPS, FY2025 earnings at $4.72 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.40 EPS and FY2026 earnings at $6.02 EPS.

Other research analysts also recently issued reports about the company. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Up 0.4 %

Halozyme Therapeutics stock opened at $57.34 on Monday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a fifty day moving average price of $51.73 and a two-hundred day moving average price of $54.42. The firm has a market cap of $7.30 billion, a price-to-earnings ratio of 18.99, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics has a fifty-two week low of $34.36 and a fifty-two week high of $65.53.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HALO. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the period. GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares in the last quarter. Finally, Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $57,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.